Radiotherapy to the primary tumor has been a controversially discussed intervention in patients with newly diagnosed metastatic prostate cancer. Results of the STAMPEDE trial indicate that overall no survival advantage can be achieved by the addition of radiotherapy however subgroups might actually have a benefit. Here, patients with low volume, oligometastatic disease were shown to benefit in a predefined subgroup analysis. In this podcast, Dr. Parker provides insight on the practice changing impact of the STAMPE trial and gives an outlook what is next on the horizon in metastatic prostate cancer therapy.

Read the full Abstract on the ESMO Open website: https://esmoopen.bmj.com/